Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive Company director reports a small equity transaction. A board member acquired 333 shares of Colgate-Palmolive common stock on 01/02/2026 at a price of $78.66 per share, according to a Form 4 filing. After this transaction, the director beneficially owns 39,648 shares held directly.
The filing explains that the transaction reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The form is signed by an attorney-in-fact on 01/06/2026, indicating the report was made on the director’s behalf.
Colgate-Palmolive Company director reports deferred stock award
A director of Colgate-Palmolive Company reported acquiring 301 shares of common stock on 01/02/2026 at a price of $78.66 per share. According to the footnote, this reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, rather than a market purchase for cash.
Following this transaction, the director beneficially owns 37,195 shares directly and 4,719 shares indirectly through a trust. The filing confirms the individual’s status as a director and that the report is filed for one reporting person.
Colgate-Palmolive Company Chairman, President & CEO and director reported a routine tax-related share withholding. On 12/03/2025, the executive disposed of 1,307 shares of common stock at $78.2 per share, coded as an "F" transaction, meaning shares were withheld to cover Medicare and income tax owed on previously granted restricted stock units. The executive continues to hold those restricted stock units, reduced only by the shares used for required tax withholding.
After this transaction, the executive beneficially owns 338,756 shares directly. Additional indirect holdings include 53,923 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive Company officer reports small share withholding for taxes. A company officer serving as COO, Eur., APac, Afr Eur, Skin reported a Form 4 transaction involving Colgate-Palmolive common stock. On 12/03/2025, 221 shares of common stock were disposed of at $78.2 per share, coded as transaction type F, which represents shares withheld to cover Medicare and income tax on previously granted restricted stock units under the company’s incentive compensation plan.
After this tax withholding, the officer beneficially owns 10,415 shares directly, 4,538 shares indirectly through the issuer's 401(k) plan trustee, and 60,745 shares indirectly through a trust. The filing notes that the officer continues to hold the original restricted stock units granted, reduced only by the amount required for this tax withholding.
Colgate-Palmolive Company’s Chief Financial Officer, reported on a Form 4 that shares of company stock were withheld to cover taxes on previously granted restricted stock units. On 12/03/2025, 385 shares of common stock were disposed of at a price of $78.2 per share through tax withholding, coded as transaction type "F," which indicates payment of tax liability from equity awards.
After this transaction, the officer beneficially owns 55,310 shares of Colgate-Palmolive common stock directly, and an additional 326 shares indirectly through the issuer’s 401(k) plan trustee. The filing clarifies that the underlying restricted stock units remain held by the officer, reduced only by the amount required for Medicare and income tax withholding.
Colgate-Palmolive Company executive Kristine Hutchinson, EVP and Controller, reported a small tax-related stock transaction. On 12/03/2025, 41 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share under transaction code "F," which indicates shares were withheld to cover taxes on previously granted restricted stock units.
After this transaction, Hutchinson beneficially owns 11,879 shares of Colgate-Palmolive common stock directly and 8,497 shares indirectly through the issuer's 401(k) plan trustee. The explanation notes that she continues to hold the original restricted stock units, reduced only by the number of shares withheld to satisfy Medicare and income tax obligations.
Colgate-Palmolive Company’s Chief Growth Officer reported a small share transaction involving company stock. On 12/03/2025, 156 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share in a transaction coded “F,” which indicates shares were withheld by the company to cover Medicare and income tax obligations tied to previously granted restricted stock units. After this tax withholding, the officer beneficially owns 17,645 shares directly and 5,416 shares indirectly through the issuer’s 401(k) plan trustee. The underlying restricted stock units remain in place, reduced only by the shares used for required tax withholding.
Colgate-Palmolive (CL) reported a routine insider tax-withholding transaction by its Chief Legal Officer and Secretary. On 12/03/2025, the executive had 213 shares of common stock withheld at a price of $78.2 per share, coded as an "F" transaction, which indicates shares were withheld to cover Medicare and income tax obligations on previously granted restricted stock units under the company’s incentive compensation plan.
After this non-open-market transaction, the executive beneficially owns 76,406 shares of Colgate-Palmolive common stock directly and an additional 1,825 shares indirectly through the issuer's 401(k) plan trustee. The filing notes that the restricted stock units themselves continue to be held, reduced only by the amount of shares withheld for taxes.
Colgate-Palmolive Company (CL) reported an insider stock transaction by its Chief Human Resources Officer. On 11/21/2025, the officer sold 1,237 shares of Colgate-Palmolive common stock at a price of $80.89 per share. After this sale, the officer beneficially owned 13,751 shares directly and 8,058 shares indirectly through the issuer's 401(k) plan trustee. The filing was made on a Form 4, which discloses changes in insider ownership.
Colgate-Palmolive Company announced the issuance and sale of €600,000,000 aggregate principal amount of its 3.250% Senior Notes due 2035. The company entered into an underwriting agreement on November 3, 2025 with Barclays Bank PLC and Banco Bilbao Vizcaya Argentaria, S.A., acting as representatives of the underwriters.
The notes were offered under Colgate-Palmolive’s automatic shelf registration statement on Form S-3 (File No. 333-275201), with a Prospectus Supplement dated November 3, 2025 and filed November 5, 2025. The notes were issued on November 10, 2025 under the existing Indenture dated November 15, 1992 with The Bank of New York Mellon as trustee. The underwriting agreement, the Indenture, and the form of the notes were filed as exhibits.